HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
Top Cited Papers
Open Access
- 8 February 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 104 (5), 863-870
- https://doi.org/10.1038/sj.bjc.6606092
Abstract
Recently, a Risk of Ovarian Malignancy Algorithm (ROMA) utilising human epididymis secretory protein 4 (HE4) and CA125 successfully classified patients as presenting a high or low risk for epithelial ovarian cancer (EOC). We validated this algorithm in an independent prospective study. Women with a pelvic mass, who were scheduled to have surgery, were enrolled in a prospective study. Preoperative serum levels of HE4 and CA125 were measured in 389 patients. The performance of each of the markers, as well as that of ROMA, was analysed. When all malignant tumours were included, ROMA (receiver operator characteristic (ROC)-area under curve (AUC)=0.898) and HE4 (ROC-AUC)=0.857) did not perform significantly better than CA125 alone (ROC–AUC=0.877). Using a cutoff for ROMA of 12.5% for pre-menopausal patients, the test had a sensitivity of 67.5% and a specificity of 87.9%. With a cutoff of 14.4% for post-menopausal patients, the test had a sensitivity of 90.8% and a specificity of 66.3%. For EOC vs benign disease, the ROC–AUC of ROMA increased to 0.913 and for invasive EOC vs benign disease to 0.957. This independent validation study demonstrated similar performance indices to those recently published. However, in this study, HE4 and ROMA did not increase the detection of malignant disease compared with CA125 alone. Although the initial reports were promising, measurement of HE4 serum levels does not contribute to the diagnosis of ovarian cancer.Keywords
This publication has 25 references indexed in Scilit:
- Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic massAmerican Journal of Obstetrics and Gynecology, 2010
- Use of a Symptom Index, CA125, and HE4 to predict ovarian cancerGynecologic Oncology, 2010
- Ultrasound methods to distinguish between malignant and benign adnexal masses in the hands of examiners with different levels of experienceUltrasound in Obstetrics & Gynecology, 2009
- Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cystsBritish Journal of Cancer, 2009
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massGynecologic Oncology, 2009
- Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterusGynecologic Oncology, 2008
- Systematic Evaluation of Candidate Blood Markers for Detecting Ovarian CancerPLOS ONE, 2008
- Bead-Based ELISA for Validation of Ovarian Cancer Early Detection MarkersClinical Cancer Research, 2006
- Serum tumor marker immunoassays in gynecologic oncology: Establishment of reference valuesAmerican Journal of Obstetrics and Gynecology, 1996
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983